Nuvectis Pharma (NASDAQ:NVCT) Stock Price Down 2.5% – Here’s Why

Nuvectis Pharma, Inc. (NASDAQ:NVCT)’s stock price was down 2.5% on Tuesday . The stock traded as low as $9.47 and last traded at $9.51. Approximately 76,117 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 126,054 shares. The stock had previously closed at $9.75.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

Nuvectis Pharma Price Performance

The stock has a market cap of $246.99 million, a price-to-earnings ratio of -7.11 and a beta of -0.07. The company’s 50 day moving average is $9.22 and its 200 day moving average is $8.43.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. Sell-side analysts predict that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NVCT. Vanguard Group Inc. raised its holdings in shares of Nuvectis Pharma by 4.8% in the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock worth $4,206,000 after acquiring an additional 31,903 shares during the last quarter. Iridian Asset Management LLC CT increased its position in Nuvectis Pharma by 44.5% during the 4th quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock worth $4,427,000 after purchasing an additional 180,699 shares in the last quarter. Baldwin Wealth Partners LLC MA raised its stake in Nuvectis Pharma by 11.2% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock valued at $2,942,000 after purchasing an additional 39,164 shares during the last quarter. Occam Crest Management LP lifted its holdings in Nuvectis Pharma by 31.0% in the 4th quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock valued at $2,869,000 after purchasing an additional 90,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Nuvectis Pharma by 11.8% during the 4th quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after purchasing an additional 38,291 shares during the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.